Homegrown drug major, Aurobindo Pharma today said it has received a final approval from the US health regulator for sale of Ceftazidime, used to treat respiratory infections, in the American market.
The company has bagged the final approval from US Food and Drug Administration for two variants of the drug, it said in a filing to the Bombay Stock Exchange (BSE).
The two variants -- Ceftazidime injections in strengths of 500 mg, 1 gram, 2 gram and 6 gram -- are used to treat infections caused by susceptible gram like septicemia, lower respiratory tract infections and abdominal cavity.
The two variants are generic equivalents to GlaxoSmithKilne's product 'Fortaz', with a market size of $30 million in the US.
The company currently has 89 final approvals from the US FDA for its new drugs.
